MedTrace Logo

Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

NCT06743646 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2025-01-03

No results posted yet for this study

Summary

This is a multi-center, randomized and controlled phase 3 clinical trial.

Conditions

  • Bietti Crystalline Corneoretinal Dystrophy
  • Bietti Crystalline Dystrophy

Interventions

DRUG

ZVS101e

subretinal injection of ZVS101e

Sponsors & Collaborators

  • Chigenovo Co., Ltd

    lead NETWORK

Principal Investigators

  • Jinlu Zhang, MD · Chigenovo Co., Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-27
Primary Completion
2026-06-30
Completion
2030-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06743646 on ClinicalTrials.gov